Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
A Phase III, Multicenter, Placebo-controlled, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of PROCHYMAL® (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Induction of Remission in Subjects Experiencing Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated:  12/6/2017
Weill-Cornell Medical College
mi
from
New York, NY
Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
A Phase III, Multicenter, Placebo-controlled, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of PROCHYMAL® (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Induction of Remission in Subjects Experiencing Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated: 12/6/2017
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
A Phase III, Multicenter, Placebo-controlled, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of PROCHYMAL® (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Induction of Remission in Subjects Experiencing Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated:  12/6/2017
Mount Sinai School of Medicine
mi
from
New York, NY
Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
A Phase III, Multicenter, Placebo-controlled, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of PROCHYMAL® (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Induction of Remission in Subjects Experiencing Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated: 12/6/2017
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
A Phase III, Multicenter, Placebo-controlled, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of PROCHYMAL® (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Induction of Remission in Subjects Experiencing Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated:  12/6/2017
University of Texas Health Science Center
mi
from
Houston, TX
Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
A Phase III, Multicenter, Placebo-controlled, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of PROCHYMAL® (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Induction of Remission in Subjects Experiencing Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated: 12/6/2017
University of Texas Health Science Center
mi
from
Houston, TX
Click here to add this to my saved trials
Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
A Phase III, Multicenter, Placebo-controlled, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of PROCHYMAL® (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Induction of Remission in Subjects Experiencing Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated:  12/6/2017
Royal Adelaide Hospital
mi
from
Adelaide,
Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
A Phase III, Multicenter, Placebo-controlled, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of PROCHYMAL® (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Induction of Remission in Subjects Experiencing Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated: 12/6/2017
Royal Adelaide Hospital
mi
from
Adelaide,
Click here to add this to my saved trials
Genetics of Fatty Liver Disease in Children
Genetics of Fatty Liver Disease in Childhood Obesity.
Status: Enrolling
Updated:  12/6/2017
Yale University
mi
from
New Haven, CT
Genetics of Fatty Liver Disease in Children
Genetics of Fatty Liver Disease in Childhood Obesity.
Status: Enrolling
Updated: 12/6/2017
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Compassionate Use of Omegaven IV Fat Emulsion
Compassionate Use of Omegaven IV Fat Emulsion
Status: Enrolling
Updated:  12/6/2017
Staten Island University Hospital
mi
from
Staten Island, NY
Compassionate Use of Omegaven IV Fat Emulsion
Compassionate Use of Omegaven IV Fat Emulsion
Status: Enrolling
Updated: 12/6/2017
Staten Island University Hospital
mi
from
Staten Island, NY
Click here to add this to my saved trials
FREE Study - Fracture Reduction Evaluation
An International Multicentric, Multidisciplinary Prospective and Randomized Study to Compare Minimally Invasive Reduction and Fixation Using the KyphX System and Radiopaque PMMA Cement to Medical Therapy Alone for the Treatment of Painful, Acute Osteopenic Vertebral Body Compression Fractures
Status: Enrolling
Updated:  12/6/2017
University of Alabama
mi
from
Birmingham, AL
FREE Study - Fracture Reduction Evaluation
An International Multicentric, Multidisciplinary Prospective and Randomized Study to Compare Minimally Invasive Reduction and Fixation Using the KyphX System and Radiopaque PMMA Cement to Medical Therapy Alone for the Treatment of Painful, Acute Osteopenic Vertebral Body Compression Fractures
Status: Enrolling
Updated: 12/6/2017
University of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Vitamin D and Coronary Calcification Study
A Phase IV, Randomized, Single-center Study of the Effects of Calcitriol and Paricalcitol on Vascular Calcification in Chronic Kidney Disease Stages 3 and 4
Status: Enrolling
Updated:  12/7/2017
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Vitamin D and Coronary Calcification Study
A Phase IV, Randomized, Single-center Study of the Effects of Calcitriol and Paricalcitol on Vascular Calcification in Chronic Kidney Disease Stages 3 and 4
Status: Enrolling
Updated: 12/7/2017
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated:  12/7/2017
Clinical Research of West Florida
mi
from
Clearwater, FL
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated: 12/7/2017
Clinical Research of West Florida
mi
from
Clearwater, FL
Click here to add this to my saved trials
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated:  12/7/2017
Shafran Gastroenterology Center
mi
from
Winter Park, FL
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated: 12/7/2017
Shafran Gastroenterology Center
mi
from
Winter Park, FL
Click here to add this to my saved trials
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated:  12/7/2017
University of Chicago
mi
from
Chicago, IL
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated: 12/7/2017
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated:  12/7/2017
Cotton-O'Neil Clinical Research Center
mi
from
Topeka, KA
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated: 12/7/2017
Cotton-O'Neil Clinical Research Center
mi
from
Topeka, KA
Click here to add this to my saved trials
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated:  12/7/2017
University of Maryland, Baltimore
mi
from
Baltimore, MD
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated: 12/7/2017
University of Maryland, Baltimore
mi
from
Baltimore, MD
Click here to add this to my saved trials
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated:  12/7/2017
Chevy Chase Clinical Research
mi
from
Chevy Chase, MD
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated: 12/7/2017
Chevy Chase Clinical Research
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated:  12/7/2017
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated: 12/7/2017
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated:  12/7/2017
Gastroenterology Center of the Midsouth
mi
from
Germantown, TN
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated: 12/7/2017
Gastroenterology Center of the Midsouth
mi
from
Germantown, TN
Click here to add this to my saved trials
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated:  12/7/2017
Vanderbilt University Medical Center
mi
from
Nashville, TN
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated: 12/7/2017
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated:  12/7/2017
Baylor University Medical Center
mi
from
Dallas, TX
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated: 12/7/2017
Baylor University Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated:  12/7/2017
McGuire Research Institute
mi
from
Richmond, VA
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated: 12/7/2017
McGuire Research Institute
mi
from
Richmond, VA
Click here to add this to my saved trials
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated:  12/7/2017
University of California at San Francisco
mi
from
San Francisco, CA
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated: 12/7/2017
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated:  12/7/2017
Saint Louis Center for Clinical Research
mi
from
Saint Louis, MO
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated: 12/7/2017
Saint Louis Center for Clinical Research
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated:  12/7/2017
St Louis Center for Clinical Studies
mi
from
Saint Louis, MO
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated: 12/7/2017
St Louis Center for Clinical Studies
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated:  12/7/2017
Weill-Cornell Medical College
mi
from
New York, NY
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated: 12/7/2017
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated:  12/7/2017
Mount Sinai School of Medicine
mi
from
New York, NY
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated: 12/7/2017
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated:  12/7/2017
Royal Adelaide Hospital
mi
from
Adelaide,
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease
Status: Enrolling
Updated: 12/7/2017
Royal Adelaide Hospital
mi
from
Adelaide,
Click here to add this to my saved trials
Feasibility Study of the Magnetic Anal Sphincter (FENIX System)
An Observational Clinical Feasibility Study of The Magnetic Anal Sphincter
Status: Enrolling
Updated:  12/7/2017
Colon and Rectal Surgery Associates, Ltd
mi
from
Minneapolis, MN
Feasibility Study of the Magnetic Anal Sphincter (FENIX System)
An Observational Clinical Feasibility Study of The Magnetic Anal Sphincter
Status: Enrolling
Updated: 12/7/2017
Colon and Rectal Surgery Associates, Ltd
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Feasibility Study of the Magnetic Anal Sphincter (FENIX System)
An Observational Clinical Feasibility Study of The Magnetic Anal Sphincter
Status: Enrolling
Updated:  12/7/2017
Providence Medical Research Center
mi
from
Spokane, WA
Feasibility Study of the Magnetic Anal Sphincter (FENIX System)
An Observational Clinical Feasibility Study of The Magnetic Anal Sphincter
Status: Enrolling
Updated: 12/7/2017
Providence Medical Research Center
mi
from
Spokane, WA
Click here to add this to my saved trials
Feasibility Study of the Magnetic Anal Sphincter (FENIX System)
An Observational Clinical Feasibility Study of The Magnetic Anal Sphincter
Status: Enrolling
Updated:  12/7/2017
Arhus Universitetshospital
mi
from
Arhus,
Feasibility Study of the Magnetic Anal Sphincter (FENIX System)
An Observational Clinical Feasibility Study of The Magnetic Anal Sphincter
Status: Enrolling
Updated: 12/7/2017
Arhus Universitetshospital
mi
from
Arhus,
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Anniston, AL
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Anniston, AL
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Birmingham, AL
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Birmingham, AL
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Birmingham, AL
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Birmingham, AL
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Dothan, AL
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Dothan, AL
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Huntsville, AL
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Huntsville, AL
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Montgomery, AL
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Montgomery, AL
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Montgomery, AL
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Montgomery, AL
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Selma, AL
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Selma, AL
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Chandler, AZ
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Chandler, AZ
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Peoria, AZ
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Peoria, AZ
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Phoenix, AZ
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Scottsdale, AZ
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Tempe, AZ
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Tempe, AZ
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Tucson, AZ
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Tucson, AZ
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Tucson, AZ
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Jonesboro, AR
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Jonesboro, AR
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Little Rock, AR
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Little Rock, AR
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Little Rock, AR
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials